Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Jazz Pharmaceuticals plc

Pfizer vs. Jazz: A Decade of SG&A Strategies

__timestampJazz Pharmaceuticals plcPfizer Inc.
Wednesday, January 1, 201440611400014097000000
Thursday, January 1, 201544911900014809000000
Friday, January 1, 201650289200014837000000
Sunday, January 1, 201754415600014784000000
Monday, January 1, 201868353000014455000000
Tuesday, January 1, 201973694200014350000000
Wednesday, January 1, 202085423300011615000000
Friday, January 1, 2021145168300012703000000
Saturday, January 1, 2022141696700013677000000
Sunday, January 1, 2023134310500014771000000
Monday, January 1, 202414730000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of SG&A: Pfizer vs. Jazz Pharmaceuticals

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Pfizer Inc. and Jazz Pharmaceuticals plc have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A expenses have consistently dwarfed those of Jazz, averaging around 14 times higher. Notably, Pfizer's expenses peaked in 2015, reaching nearly $14.8 billion, while Jazz saw a significant rise in 2021, with expenses increasing by over 250% from 2014 levels. This divergence highlights Pfizer's expansive global operations compared to Jazz's more focused approach. As the industry faces new challenges, understanding these financial strategies offers valuable insights into how these giants navigate market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025